STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANNX
  4. [Form 4] Annexon, Inc. Insider Trading Activity

[Form 4] Annexon, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ANNX logo
Annexon, Inc.

NASDAQ:ANNX

ANNX Rankings

#5215 Ranked by Market Cap
N/A Ranked by Dividends

ANNX Latest News

Jun 18, 2025
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
May 29, 2025
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
May 19, 2025
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
May 16, 2025
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2025
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

ANNX Latest SEC Filings

Jul 16, 2025
[Form 4] Annexon, Inc. Insider Trading Activity
Jul 16, 2025
[Form 4] Annexon, Inc. Insider Trading Activity
Jul 14, 2025
[144] Annexon, Inc. SEC Filing
Jul 14, 2025
[144] Annexon, Inc. SEC Filing
Jul 14, 2025
[144] Annexon, Inc. SEC Filing

ANNX Stock Data

297.33M
101.68M
0.58%
106.98%
9.93%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRISBANE